Skip to main content
GENFLOW BIOSCIENCES PLC logo

GENFLOW BIOSCIENCES PLC — Investor Relations & Filings

Ticker · GENF ISIN · GB00BP2C3V08 LEI · 213800HVOFXRXVEGDN62 IL Professional, scientific and technical activities
Open in API
Filings indexed 142 across all filing types
Latest filing 2024-10-22 Regulatory Filings
Country GB United Kingdom
Listing IL GENF

About GENFLOW BIOSCIENCES PLC

https://genflowbio.com/

Genflow Biosciences PLC is a biotechnology company developing gene therapies that target the aging process. The company's primary mission is to slow or halt aging and reduce the incidence of age-related diseases in both humans and dogs, thereby extending healthspan. Its lead therapeutic candidate, GF-1002, is a gene therapy that delivers a centenarian variant of the Sirtuin 6 (SIRT6) gene. This specific gene variant has been identified in individuals who live to 100 years or more and has demonstrated promising results in pre-clinical studies.

Recent filings

Filing Released Lang Actions
Genflow Secures Non-Dilutive Financial Support
Regulatory Filings Classification · 99% confidence The document begins with an RNS Number and is dated October 22, 2024. It explicitly states that the information is deemed inside information under MAR and is published via a Regulatory Information Service (RNS). The content announces that Genflow Biosciences has secured €4 Million in non-dilutive financial support from the Wallonia Region for GF-1002 development. This is a specific corporate announcement released through the official regulatory news service (RNS) of the London Stock Exchange, rather than being a full financial report (like 10-K or IR) or a specific type of filing like a Director's Dealing or Proxy Statement. Since it is a general regulatory announcement disseminated via RNS that doesn't fit the other specific categories, the most appropriate classification is the general Regulatory Filings fallback code.
2024-10-22 English
Half-year Report
Earnings Release Classification · 99% confidence The document explicitly states 'HALF YEAR RESULTS' and provides financial statements (Consolidated Statement of Financial Position, Comprehensive Income, and Cash Flows) for the 'six-month period ended 30 June 2024'. This content structure and reporting period (six months) are characteristic of an Interim or Quarterly Report, which corresponds to the 'Interim / Quarterly Report' definition (Code: IR). Although it is a comprehensive report, it is not the Annual Report (10-K). It is not merely an announcement of a report (RPA) because it contains the full financial tables and management discussion, despite being relatively short compared to a full 10-K. H1 2024
2024-09-30 English
Group of companies' accounts made up to 2023-12-31
Regulatory Filings
2024-07-01 English
Print of Ordinary and Special Resolutions
AGM Information Classification · 99% confidence The document explicitly states it is the 'PRINT OF ORDINARY AND SPECIAL RESOLUTIONS' passed at an 'annual general meeting' (AGM) held on June 27, 2024. It details the resolutions voted upon, including receiving the Annual Report, approving remuneration, re-appointing auditors, and authorizing share allotment powers. This content directly relates to the formal proceedings and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-06-28 English
Result of AGM
AGM Information Classification · 99% confidence The document explicitly states 'Results of Annual General Meeting' and confirms that 'all resolutions proposed at the Annual General Meeting held earlier today were duly passed.' This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, or in this case, the results thereof. Although it is a short regulatory announcement (RNS format), the specific content is about the AGM results, making AGM-R the most precise classification over the general RNS fallback.
2024-06-27 English
Strengthening of Pre-Clinical Efforts
Regulatory Filings Classification · 99% confidence The document is clearly identified as an RNS announcement (RNS Number : 0280U) released on June 27, 2024. It contains operational updates regarding FDA guidance, selection of CDMO/CROs, and progress on pre-clinical programs. While it discusses business developments, it is structured as a formal regulatory news service release, not a comprehensive financial report (like 10-K or IR) or a specific announcement like a dividend (DIV) or director dealing (DIRS). Since it is a general regulatory announcement distributed via RNS that doesn't fit a more specific category (like ER or CT), the most appropriate classification is the general Regulatory Filings category, RNS.
2024-06-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.